TECHWIRE 30
(CIX: WRAL30)  1,102.96  up arrow+11.29  (1.03 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: Apple)  108.00  up arrow+1.02  (0.95 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NY: QUINTILES)  58.54  up arrow+2.24  (3.98 %)  Updated: 06:40 PM EDT, Oct 31 2014
(OP: BASF SE)  88.22  up arrow+1.3  (1.5 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: BioCryst)  11.72  down arrow-0.34  (-2.82 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: BioDelivery)  17.40  down arrow-0.39  (-2.19 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: CEMP)  13.60  down arrow-0.09  (-0.66 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: Cisco Systems)  24.47  up arrow+0.39  (1.62 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: Cree)  31.48  down arrow-0.03  (-0.1 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: DARA)  0.85  down arrow-0.03  (-3.3 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NY: EMC CORPORATION)  28.73  up arrow+0.27  (0.95 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NQ: Extreme Networks)  3.59  up arrow+0.06  (1.7 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: FB)  74.99  up arrow+0.88  (1.19 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NY: GLAXOSMITHKLINE)  45.49  up arrow+0.35  (0.78 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NQ: GOOG)  559.08  up arrow+8.77  (1.59 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NY: IBM)  164.40  up arrow+0.05  (0.03 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NY: LH)  109.29  up arrow+1.9  (1.77 %)  Updated: 06:40 PM EDT, Oct 31 2014
(OP: Lenovo Group)  29.49  down arrow-0.07  (-0.24 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NY: MRK)  57.94  up arrow+0.63  (1.1 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NQ: Microsoft Corp)  46.95  up arrow+0.9  (1.95 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: NTAP)  42.80  up arrow+0.69  (1.64 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NY: NOVARTIS AG)  92.69  up arrow+0.74  (0.8 %)  Updated: 06:40 PM EDT, Oct 31 2014
(OP: Novozymes A/S)  46.30  down arrow-0.01  (-0.02 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NY: PFIZER)  29.95  up arrow+0.11  (0.37 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NQ: Pozen)  9.07  down arrow-0.1  (-1.09 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NY: RED HAT)  58.92  up arrow+0.67  (1.15 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NQ: BBRY)  10.50  up arrow+0.02  (0.19 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: Salix)  143.85  down arrow-0.65  (-0.45 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: SQI)  14.91  down arrow-2.02  (-11.93 %)  Updated: 08:10 PM EDT, Oct 31 2014

Posts tagged “Salix”

Updated February 15, 2013

Premium Lock Feds subpoena Salix, ask about drug promotion practices

Salix Federal prosecutors have questions about how Salix Pharmaceuticals (NASDAQ:SLXP) sells and promotes its drugs, including its top-selling product Xifaxan.

January 3, 2013

Premium Lock Drug approval sends Salix shares up nearly 5%

Salix Shares in Salix Pharmaceuticals rose nearly 5 percent Wednesday on news that the FDA had approved its new drug for the treatment of AIDS-related diarrhea.

January 2, 2013

Premium Lock FDA approves new Salix drug to treat AIDS-related diarrhea

Salix Shares in Salix Pharmaceuticals rose more than 3 percent Wednesday on news that the FDA had approved its new drug for the treatment of AIDS-related diarrhea.

November 8, 2012

Premium Lock Earnings: Salix; PowerSecure; Pozen; BioCryst

Bulldog Inside the Bulldog Blog: Revenues up at Salix; record revenues for PowerSecure; Pozen cuts losses; net loss declines at Biocryst;

Updated October 23, 2012

Premium Lock Raleigh drug firm Salix sponsors documentary on liver disease

Salix Pharmaceuticals and the American Liver Foundation back a new documentary about hepatic encephalopathy, or HE, which was directed by Academy Award winner Cynthia Wade.

Salix backs "HE" documentary Salix backs "HE" documentary

September 5, 2012

Premium Lock FDA again delays Salix gastrointestinal drug

Salix The FDA has again delayed an approval decision for a new diarrhea drug from Salix Pharmaceuticals.

August 9, 2012

Premium Lock Salix pays $10M upfront for possible treatment of Crohn's Disease

Salix The Raleigh-based pharmaceutical firm licenses rights to an extended release version of the drug Rifaximin that targets gastrointestinal and respiratory ailments.

August 9, 2012

Premium Lock Earnings: Salix, Cempra, Targacept, Cornerstone

Earnings    Four North Carolina-based life science firms report an overall mixed bag of results, but Raleigh-based Salix reports huge jump in sales.

Updated July 31, 2012

Premium Lock Salix delays big hiring plans after FDA rejects drug

Salix Salix will no longer add an additional 160 primary-care sales representatives later this year and plans to update its 2012 earnings forecast when it releases second-quarter results on Aug. 8.

July 30, 2012

Premium Lock In the news: Quintiles, Salix, Furiex, AAD

Bulldog Inside the Bulldog Blog: Quintiles lands drug promotion deal; Salix seeks FDA meeting about drug response; Furiex resubmits diabetes drug; Advanced Animal Diagnostics adds two execs.

May 8, 2012

Premium Lock Salix revenue rises 62% in first quarter, beats Street

Salix Salix Pharmaceuticals announced on Monday a 62 percent increase in its first quarter revenue for 2012 with total product revenue at $171.1 million thanks in part to the company's leading drug Xifaxan.

Tags: Salix
May 1, 2012

Premium Lock FDA delays decision on Salix drug to treat HIV-related diarrhea

HIV research Salix had been scheduled for a June 5 decision date on its experimental diarrhea treatment crofelemer. But the Raleigh company says FDA regulators need more time to review the submission.

April 26, 2012

Premium Lock FDA oushes back review for Salix constipation treatment

Salix An approval decision was expected on April 27. But the U.S. Food and Drug Administration has notified the Raleigh-based company that it needs more time. The new target date to issue an approval decision is July 27.

March 13, 2012

Premium Lock Raleigh-based Salix Pharmaceuticals to raise $600M

Salix Salix says it will repurchase outstanding convertible senior notes that are due in 2028. The company also plans to repurchase up to $75 million of its outstanding common stock and will also use proceeds for corporate purposes.

February 28, 2012

Premium Lock How long before Salix Pharmaceuticals hits $1B?

Salix After a 60 percent jump in revenue in 2011 to $540 million, the Raleigh-based drug firm forecasts a 36 percent jump in 2012 to $735 million.

February 22, 2012

Premium Lock In the news: Visilink's LED wireless; MercuryGate grows; Salix drug trial; Furiex cuts losses; iContact donations; Software Toolbox update

Tech briefs Local tech briefs: Cary-based Visilink unveils LED-based wireless; Cary firm MercuryGate expands to Asia; Salix launches new drug trial; Furiex cuts its losses; iContact donates $200,000; Charlotte firm updates automation software.

Updated February 7, 2012

Premium Lock Salix drug receives priority FDA review, but partner wants it back

Salix The Raleigh firm is tied up in a law suit over the development of the drug that's intended to help AIDS patients suffering with diarrhea.

December 21, 2011

Premium Lock Salix's pill version of Relistor succeeds in phase 3; NDA expected in 2012

Salix Salix released successful phase 3 clinical trial results for the oral version of Relistor and now plans to submit a new drug application for the compound in the middle of 2012.

November 15, 2011

Premium Lock Salix faces tough questions from FDA about expanded use of drug

Salix Salix is preparing for new set of Xifaxan phase 3 clinical trials studying the irritable bowel syndrome indication, which puts approval about two years away. But first the company will meet with an FDA advisory panel on Wednesday, eight months after receiving the complete response letter from the agency declining approval on Xifaxan as a new IBS treatment.

Updated November 15, 2011

Premium Lock FDA raises questions about Salix drug; shares fall 10%

Salix Triangle-based Salix wants to expand use of its bowel drug but the FDA raised questions that concern an analyst who follows the company.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Scroll